• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阐明五聚谷氨酸序列的结构-活性关系与胆囊收缩素受体 2 亚型。

Elucidating the Structure-Activity Relationship of the Pentaglutamic Acid Sequence of Minigastrin with Cholecystokinin Receptor Subtype 2.

机构信息

Department of Chemistry and Applied Biosciences (D-CHAB), Laboratory of Organic Chemistry (LOC) , ETH , CH-8093 Zurich , Switzerland.

Department of Chemistry and Applied Biosciences (D-CHAB), Institute of Pharmaceutical Sciences (IPW) , ETH , CH-8093 Zurich , Switzerland.

出版信息

Bioconjug Chem. 2019 Mar 20;30(3):657-666. doi: 10.1021/acs.bioconjchem.8b00849. Epub 2019 Jan 14.

DOI:10.1021/acs.bioconjchem.8b00849
PMID:30608664
Abstract

Derivatized minigastrin analogues make up a promising class of candidates for targeting cholecystokinin receptor subtype 2 (CCK2R), which is overexpressed on cancer cells of various neuroendocrine tumors. The pentaglutamic acid sequence of minigastrin influences its biological properties. In particular, it plays a crucial role in the kidney reuptake mechanism. However, the importance of the binding affinity and interaction of this region with the receptor on a molecular level remains unclear. To elucidate its structure-activity relationship with CCK2R, we replaced this sequence with various linkers differing in their amount of anionic charge, structural characteristics, and flexibility. Specifically, a flexible aliphatic linker, a linker with only three d-Glu residues, and a structured linker with four adjacent β-glutamic acid residues were evaluated and compared to the lead compound PP-F11N (DOTA-[d-Glu,Nle]gastrin-13). 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was conjugated to the minigastrin derivatives, which allowed radiolabeling with Lutetium-177. The levels of In vitro internalization into MZ-CRC1 cells and in vivo tumor uptake as well as human blood plasma stability increased in the following order: aliphatic linker < three d-Glu < (β-Glu) < (d-Glu). The in vitro and in vivo behavior was therefore significantly improved with anionic charges. Computational modeling of a CCK2 receptor-ligand complex revealed ionic interactions between cationic residues (Arg and His) of the receptor and anionic residues of the ligand in the linker.

摘要

衍生的小胃泌素类似物构成了一类有前途的候选物,可用于靶向胆囊收缩素受体亚型 2(CCK2R),该受体在各种神经内分泌肿瘤的癌细胞上过度表达。小胃泌素的五聚谷氨酸序列影响其生物学特性。特别是,它在肾脏重摄取机制中起着至关重要的作用。然而,该区域与受体在分子水平上的结合亲和力和相互作用的重要性仍不清楚。为了阐明其与 CCK2R 的结构-活性关系,我们用在阴离子电荷、结构特征和灵活性方面存在差异的各种接头取代了该序列。具体来说,评估并比较了柔性脂肪族接头、仅含三个 d-Glu 残基的接头和具有四个相邻β-谷氨酸残基的结构接头与先导化合物 PP-F11N(DOTA-[d-Glu,Nle]gastrin-13)。1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)与小胃泌素衍生物缀合,允许用镥-177 进行放射性标记。MZ-CRC1 细胞内内化水平、体内肿瘤摄取以及人血浆稳定性按以下顺序增加:脂肪族接头 < 三个 d-Glu <(β-Glu)<(d-Glu)。因此,阴离子电荷使体外和体内行为得到了显著改善。CCK2 受体-配体复合物的计算建模揭示了受体中的阳离子残基(Arg 和 His)与配体接头中的阴离子残基之间的离子相互作用。

相似文献

1
Elucidating the Structure-Activity Relationship of the Pentaglutamic Acid Sequence of Minigastrin with Cholecystokinin Receptor Subtype 2.阐明五聚谷氨酸序列的结构-活性关系与胆囊收缩素受体 2 亚型。
Bioconjug Chem. 2019 Mar 20;30(3):657-666. doi: 10.1021/acs.bioconjchem.8b00849. Epub 2019 Jan 14.
2
Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?以胆囊收缩素-2 受体为靶点的迷你胃泌素类似物 Lu-DOTA-PP-F11N:使用蛋白酶抑制剂是否能进一步改善体内分布?
J Nucl Med. 2019 Mar;60(3):393-399. doi: 10.2967/jnumed.118.207845. Epub 2018 Jul 12.
3
Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.针对酶降解的最小胃泌素类似物的位点特异性稳定化,以增强胆囊收缩素-2 受体靶向。
Theranostics. 2018 Apr 16;8(11):2896-2908. doi: 10.7150/thno.24378. eCollection 2018.
4
Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [Lu]Lu-PP-F11N.mTORC1 的药理学抑制可增加放射性标记的 minigastrin 类似物 [Lu]Lu-PP-F11N 对 CCKBR 特异性肿瘤摄取。
Theranostics. 2020 Aug 29;10(24):10861-10873. doi: 10.7150/thno.45440. eCollection 2020.
5
Lu Labeled Cyclic Minigastrin Analogues with Therapeutic Activity in CCK2R Expressing Tumors: Preclinical Evaluation of a Kit Formulation.Lu 标记的具有 CCK2R 表达肿瘤治疗活性的环最小胃泌素类似物:试剂盒配方的临床前评估。
Mol Pharm. 2017 Sep 5;14(9):3045-3058. doi: 10.1021/acs.molpharmaceut.7b00241. Epub 2017 Aug 7.
6
Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide.使用放射性标记的二价胃泌素肽靶向表达CCK-2受体的肿瘤。
J Nucl Med. 2009 Dec;50(12):2082-9. doi: 10.2967/jnumed.109.064808. Epub 2009 Nov 12.
7
99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.99mTc标记以及HYNIC和(Nα-组氨酸)乙酸修饰的[D-谷氨酸1]-小胃泌素的体外和体内评价
Bioconjug Chem. 2004 Jul-Aug;15(4):864-71. doi: 10.1021/bc0300807.
8
In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin (111)In-radioligands.体内抑制中性内肽酶可增强截短型胃泌素(1-11)放射性配体的诊断潜力。
Nucl Med Biol. 2015 Nov;42(11):824-32. doi: 10.1016/j.nucmedbio.2015.07.009. Epub 2015 Jul 29.
9
Stereochemistry of amino acid spacers determines the pharmacokinetics of (111)In-DOTA-minigastrin analogues for targeting the CCK2/gastrin receptor.氨基酸间隔臂的立体化学决定了用于靶向CCK2/胃泌素受体的(111)铟-DOTA-胃泌素类似物的药代动力学。
Bioconjug Chem. 2015 Jun 17;26(6):1113-9. doi: 10.1021/acs.bioconjchem.5b00187. Epub 2015 May 20.
10
Comparative biodistribution of 12 ¹¹¹In-labelled gastrin/CCK2 receptor-targeting peptides.125I 标记的胃泌素/胆囊收缩素 2 受体靶向肽的比较生物分布。
Eur J Nucl Med Mol Imaging. 2011 Aug;38(8):1410-6. doi: 10.1007/s00259-011-1806-0. Epub 2011 Apr 2.

引用本文的文献

1
Methyl scanning approach for enhancing the biological activity of the linear peptidic natural product, efrapeptin C.用于增强线性肽类天然产物埃弗拉肽素C生物活性的甲基扫描方法
Chem Sci. 2024 Oct 19;15(46):19390-19399. doi: 10.1039/d4sc04384g. eCollection 2024 Nov 27.
2
Investigation of the structure-activity relationship at the N-terminal part of minigastrin analogs.胃泌素小肽类似物N端部分的构效关系研究。
EJNMMI Res. 2023 Jul 8;13(1):65. doi: 10.1186/s13550-023-01016-y.
3
Elucidating the molecular determinants in the process of gastrin C-terminal pentapeptide amide end activating cholecystokinin 2 receptor by Gaussian accelerated molecular dynamics simulations.
通过高斯加速分子动力学模拟阐明胃泌素C末端五肽酰胺激活胆囊收缩素2受体过程中的分子决定因素。
Front Pharmacol. 2023 Jan 23;13:1054575. doi: 10.3389/fphar.2022.1054575. eCollection 2022.
4
Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals.胆囊收缩素-2受体靶向放射性药物的临床前开发与临床转化进展
Cancers (Basel). 2021 Nov 18;13(22):5776. doi: 10.3390/cancers13225776.
5
Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin Lu-PP-F11N.用胃泌素小肽类似物Lu-PP-F11N改善肿瘤靶向性。
Cancers (Basel). 2021 May 27;13(11):2629. doi: 10.3390/cancers13112629.
6
1,5-Disubstituted 1,2,3-Triazoles as Amide Bond Isosteres Yield Novel Tumor-Targeting Minigastrin Analogs.作为酰胺键生物电子等排体的1,5-二取代-1,2,3-三唑产生新型肿瘤靶向性小胃泌素类似物。
ACS Med Chem Lett. 2021 Mar 16;12(4):585-592. doi: 10.1021/acsmedchemlett.0c00636. eCollection 2021 Apr 8.
7
Evaluation of Actinium-225 Labeled Minigastrin Analogue [Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy.用于靶向α粒子治疗的锕-225标记的迷你胃泌素类似物[Ac]Ac-DOTA-PP-F11N的评估
Pharmaceutics. 2020 Nov 12;12(11):1088. doi: 10.3390/pharmaceutics12111088.
8
Permanent Photodynamic Activation of the Cholecystokinin 2 Receptor.胆囊收缩素 2 受体的永久光动力学激活。
Biomolecules. 2020 Feb 4;10(2):236. doi: 10.3390/biom10020236.
9
Cholecystokinin 2 Receptor Agonist Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study.胆囊收缩素 2 受体激动剂 Lu-PP-F11N 用于治疗甲状腺髓样癌的放射性核素治疗:Lumed 阶段 0a 研究结果。
J Nucl Med. 2020 Apr;61(4):520-526. doi: 10.2967/jnumed.119.233031. Epub 2019 Sep 13.